Clinical usefulness of ramucirumab plus paclitaxel for unresectable and recurrent gastric cancer

INTRODUCTION: Recently in Japan, Ramucirumab (RAM) became the first anti-angiogenic agent to be approved for second-line treatment of gastric cancer. In the present study, we aimed to evaluate the efficacy and safety of RAM plus paclitaxel (PTX) in patients with unresectable and recurrent gastric ca...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Fukushima J Med Sci
Asıl Yazarlar: Hayase, Suguru, Yamada, Leo, Ujiie, Daisuke, Nirei, Azuma, Tada, Takeshi, Hanayama, Hiroyuki, Monma, Tomoyuki, Saze, Zenichiro, Ohki, Shinji, Kono, Koji
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: The Fukushima Society of Medical Science 2019
Konular:
Original Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6509409/
https://ncbi.nlm.nih.gov/pubmed/30996218
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5387/fms.2018-12
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller